Also trades as: AFP.AX (ASX) · $vol 0M
AFT.NZ NZE
AFT Pharmaceuticals Limited
1W: -0.5%
1M: -0.2%
3M: +17.8%
YTD: +17.5%
1Y: +68.7%
3Y: +23.1%
5Y: -1.6%
NZ$4.30 ($2.40)
-0.07 (-1.60%)
Weekly Expected Move ±2.4%
NZ$4
NZ$4
NZ$4
NZ$4
NZ$5
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$255M
+23.9% ▲
5Y CAGR: +17.7%
Gross Profit
$111M
+24.0% ▲
5Y CAGR: +17.9%
Operating Income
$25M
+112.5% ▲
5Y CAGR: +17.0%
Net Income
$15M
+23.1% ▲
5Y CAGR: +13.6%
EPS (Diluted)
$0.14
+27.3% ▲
5Y CAGR: +14.6%
EBITDA
$29M
+32.7% ▲
5Y CAGR: +18.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $130M | $156M | $195M | $205M | $255M |
| YoY Growth | +15.0% | +20.0% | +25.4% | +5.2% | +23.9% |
| Cost of Revenue | $69M | $84M | $107M | $116M | $144M |
| Gross Profit | $61M | $72M | $88M | $89M | $111M |
| Gross Margin | 47.2% | 46.3% | 45.2% | 43.4% | 43.4% |
| R&D Expenses | $6M | $6M | $8M | $11M | $11M |
| SG&A Expenses | $36M | $48M | $56M | $63M | $75M |
| Operating Expenses | $42M | $55M | $67M | $77M | $86M |
| Operating Income | $20M | $19M | $24M | $12M | $25M |
| Operating Margin | 15.5% | 12.0% | 12.4% | 5.7% | 9.8% |
| Interest Expense | $2M | $3M | $4M | $3M | $2M |
| Income Before Tax | $19M | $16M | $22M | $16M | $22M |
| Tax Expense | -$1M | $5M | $6M | $5M | $8M |
| Net Income | $20M | $11M | $16M | $12M | $15M |
| Net Margin | 15.3% | 6.8% | 8.0% | 5.8% | 5.8% |
| EPS (Diluted) | $0.19 | $0.10 | $0.15 | $0.11 | $0.14 |
| EBITDA | $21M | $20M | $28M | $22M | $29M |
| Shares Outstanding | 105M | 105M | 105M | 105M | 105M |